Leadman(SZ:300289) Sou Hu Cai Jing·2025-06-03 09:25Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Lidman Biochemical Co., Ltd, including its stock price, market capitalization, and financial results for Q1 2025 [1] - On June 3, Lidman closed at 5.05 yuan, up 1.41%, with a latest price-to-book ratio of 1.65, marking a new low in 49 days and a total market value of 2.747 billion yuan [1] - The company experienced a net outflow of main funds amounting to 8.4668 million yuan on June 3, with a total outflow of 25.8327 million yuan over the past five days [1] Group 2 - Lidman specializes in the research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with key products including biochemical diagnostic reagents and automated chemiluminescence immunoassay analyzers [1] - The company has received multiple accolades, including "National High-tech Enterprise" and "Beijing Specialized and New Small and Medium-sized Enterprises," and has been recognized as a leading enterprise in the Beijing biopharmaceutical industry [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1.25172554 million yuan, a year-on-year increase of 53.73%, with a gross sales margin of 53.56% [1] Group 3 - The price-to-earnings (P/E) ratio for Lidman is reported at -37.30 (TTM) and -36.58 (static), with a price-to-book ratio of 1.65 and a total market capitalization of 2.747 billion yuan [2] - The industry average P/E ratio is 50.80 (TTM) and 49.07 (static), with an average price-to-book ratio of 4.67 and a total market capitalization of 108.36 billion yuan [2] - The industry median P/E ratio stands at 36.71 (TTM) and 36.84 (static), with a median price-to-book ratio of 2.48 and a total market capitalization of 50.19 billion yuan [2]